share_log

HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $34 Price Target

HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $34 Price Target

HC Wainwright & Co. 重申对Viridian Therapeutics的买入评级,维持34美元的目标价
Benzinga ·  2024/12/16 23:32  · 评级/大行评级

HC Wainwright & Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $34 price target.

HC Wainwright & Co. 分析师道格拉斯·曹重申了Viridian Therapeutics(纳斯达克股票代码:VRDN)的买入并维持34美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发